Who is sponsoring NCT02167594?

NCT02167594 is sponsored by Avid Radiopharmaceuticals.

What drugs are being tested in NCT02167594?

Interventions in NCT02167594: Flortaucipir F18, Brain PET scan.

What condition does NCT02167594 study?

NCT02167594 studies Progressive Supranuclear Palsy, Corticobasal Degeneration.

Is NCT02167594 still recruiting?

NCT02167594 is currently completed. Last updated 28 August 2020.

Are results published for NCT02167594?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-08-28 · How we verify

NCT02167594

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

Completed Phase 1 Results posted Last updated 28 August 2020

What this trial tests

Phase 1 trial testing Flortaucipir F18 in Progressive Supranuclear Palsy in 29 participants. Completed in 11 July 2016.

Timeline

12 August 2014

Primary endpoint
11 July 2016

11 July 2016

Quick facts

Lead sponsor	Avid Radiopharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	29
Start date	12 August 2014
Primary completion	11 July 2016
Estimated completion	11 July 2016
Sites	5 locations across United States

Drugs / interventions tested

Flortaucipir F18 — full drug profile →
Brain PET scan

Conditions studied

Progressive Supranuclear Palsy — all drugs for Progressive Supranuclear Palsy →
Corticobasal Degeneration — all drugs for Corticobasal Degeneration →

Sponsor

Avid Radiopharmaceuticals — full company profile →

Who can join

Adults 50 to 85, any sex, with Progressive Supranuclear Palsy or Corticobasal Degeneration. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Flortaucipir Imaging in PSP, CBD and Healthy Volunteers Primary · baseline and 9 month scans

A PSP/CBD (PSP = progressive supranuclear palsy; CBD = corticobasal degeneration) targeted composite Standardized Uptake Value ratio (SUVr) was calculated as the voxel-weighted average from the regional SUVr values of the left, right, and total globus pallidus and the dentate nuclei of the cerebellum for both the baseline and 9 month PET scans. Additionally, a global cortical Alzheimer's Disease (AD)-targeted cortical SUVr was calculated. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Right Dentate Baseline

Group	Value	95% CI
PSP Subjects	1.17	± 0.12
CBD Subjects	1.12	± 0.04
Healthy Volunteers	1.03	± 0.12
All Subjects	1.15	± 0.12

Right Dentate 9 months

Group	Value	95% CI
PSP Subjects	1.17	± 0.11
CBD Subjects	1.11	± 0.05
All Subjects	1.15	± 0.10

Left Dentate Baseline

Group	Value	95% CI
PSP Subjects	1.16	± 0.10
CBD Subjects	1.09	± 0.04
Healthy Volunteers	1.08	± 0.07
All Subjects	1.14	± 0.09

Left Dentate 9 months

Group	Value	95% CI
PSP Subjects	1.13	± 0.11
CBD Subjects	1.08	± 0.05
All Subjects	1.12	± 0.10

Right Globus Pallidus Baseline

Group	Value	95% CI
PSP Subjects	1.60	± 0.15
CBD Subjects	1.40	± 0.20
Healthy Volunteers	1.29	± 0.06
All Subjects	1.53	± 0.19

Right Globus Pallidus 9 Months

Group	Value	95% CI
PSP Subjects	1.58	± 0.13
CBD Subjects	1.47	± 0.19
All Subjects	1.55	± 0.15

Left Globus Pallidus Baseline

Group	Value	95% CI
PSP Subjects	1.62	± 0.15
CBD Subjects	1.56	± 0.32
Healthy Volunteers	1.30	± 0.07
All Subjects	1.58	± 0.21

Left Globus Pallidus 9 Months

Group	Value	95% CI
PSP Subjects	1.62	± 0.15
CBD Subjects	1.62	± 0.40
All Subjects	1.62	± 0.21

Adverse events — posted to ClinicalTrials.gov

Time frame: End of study for AE reporting was 48 hours after flortaucipir administration at each imaging visit.. Reporting threshold: 1.0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

PSP Subjects

Serious: 0/20 (0%)

Deaths: 0/20

CBD Subjects

Serious: 0/6 (0%)

Deaths: 1/6

Healthy Volunteers

Serious: 0/3 (0%)

Deaths: 0/3

Other adverse events (3 terms — click to expand)

Reaction	System	PSP Subjects	CBD Subjects	Healthy Volunteers
bronchial secretion retention	Respiratory, thoracic and mediastinal disorders	—	—	—
muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—
asthenia	General disorders	—	—	—

Data from ClinicalTrials.gov NCT02167594 adverse events section.

Sponsor's own description

This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

<sup>18</sup> F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.
Schonhaut DR, McMillan CT, Spina S, Dickerson BC, et al · · 2017 · cited 140× · PMID 28980714 · DOI 10.1002/ana.25060

Verify or expand the search:

Other trials of Flortaucipir F18

Trials testing the same drug.

NCT03467477 — Tau Screening Study in Subjects With Early Symptomatic AD · Phase 2 · completed
NCT03322462 — Tau Screening Study in Patients With Early Symptomatic AD · Phase 2 · completed
NCT03040713 — Flortaucipir PET Imaging in Subjects With FTD · Phase 1 · completed
NCT03052972 — Flortaucipir 18F PET Imaging in BIOCARD Study · Phase 1 · terminated
NCT03019536 — A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease · Phase 1 · completed

Other recruiting trials for Progressive Supranuclear Palsy

Currently open trials in the same condition.

NCT06588673 — Art Therapy in Progressive Supranuclear Palsy · NA · active not recruiting
NCT06647641 — The CurePSP Genetics Program · recruiting
NCT06174948 — The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders · NA · recruiting
NCT06122662 — AMX0035 and Progressive Supranuclear Palsy · Phase 2, PHASE3 · active not recruiting
NCT05956834 — A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes · active not recruiting

Other Avid Radiopharmaceuticals trials

Trials by the same sponsor.

NCT05775601 — 18F-LY3950321-01 Biodistribution and Safety Study · EARLY_PHASE1 · completed
NCT03901105 — Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease · Phase 3 · completed
NCT03901092 — A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpret · Phase 3 · completed
NCT03467477 — Tau Screening Study in Subjects With Early Symptomatic AD · Phase 2 · completed
NCT03322462 — Tau Screening Study in Patients With Early Symptomatic AD · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02167594 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Avid Radiopharmaceuticals
Last refreshed: 28 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02167594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing